{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:55:15Z","timestamp":1780588515668,"version":"3.54.1"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>In haematopoietic stem cell transplantation (HSCT), haematopoietic stem cells (HSCs) from a healthy donor replace the patient\u2019s ones. Ex vivo HSC gene therapy (HSC-GT) is a form of HSCT in which HSCs, usually from an autologous source, are genetically modified before infusion, to generate a progeny of gene-modified cells. In HSCT and HSC-GT, chemotherapy is administered before infusion to free space in the bone marrow (BM) niche, which is required for the engraftment of infused cells. Here, we review alternative chemotherapy-free approaches to niche voidance that could replace conventional regimens and alleviate the morbidity of the procedure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Sources of data<\/jats:title>\n                  <jats:p>Literature was reviewed from PubMed-listed peer-reviewed articles. No new data are presented in this article.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas of agreement<\/jats:title>\n                  <jats:p>Chemotherapy exerts short and long-term toxicity to haematopoietic and non-haematopoietic organs. Whenever chemotherapy is solely used to allow engraftment of donor HSCs, rather than eliminating malignant cells, as in the case of HSC-GT for inborn genetic diseases, non-genotoxic approaches sparing off-target tissues are highly desirable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas of controversy<\/jats:title>\n                  <jats:p>In principle, HSCs can be temporarily moved from the BM niches using mobilizing drugs or selectively cleared with targeted antibodies or immunotoxins to make space for the infused cells. However, translation of these principles into clinically relevant settings is only at the beginning, and whether therapeutically meaningful levels of chimerism can be safely established with these approaches remains to be determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Growing points<\/jats:title>\n                  <jats:p>In pre-clinical models, mobilization of HSCs from the niche can be tailored to accommodate the exchange and engraftment of infused cells. Infused cells can be further endowed with a transient engraftment advantage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas timely for developing research<\/jats:title>\n                  <jats:p>Inter-individual efficiency and kinetics of HSC mobilization need to be carefully assessed. Investigations in large animal models of emerging non-genotoxic approaches will further strengthen the rationale and encourage application to the treatment of selected diseases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bmb\/ldad017","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T02:09:47Z","timestamp":1689646187000},"page":"108-120","source":"Crossref","is-referenced-by-count":13,"title":["Mobilization-based engraftment of haematopoietic stem cells: a new perspective for chemotherapy-free gene therapy and transplantation"],"prefix":"10.1093","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6999-8479","authenticated-orcid":false,"given":"Daniele","family":"Canarutto","sequence":"first","affiliation":[{"name":"San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute , Via Olgettina, 60, 20132 Milano, MI , Italy"},{"name":"Vita-Salute San Raffaele University , Via Olgettina, 60, 20132 Milano, MI , Italy"},{"name":"Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute , Via Olgettina, 60, 20132 Milano, MI , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-5686","authenticated-orcid":false,"given":"Attya","family":"Omer Javed","sequence":"additional","affiliation":[{"name":"San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute , Via Olgettina, 60, 20132 Milano, MI , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-4623","authenticated-orcid":false,"given":"Gabriele","family":"Pedrazzani","sequence":"additional","affiliation":[{"name":"San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute , Via Olgettina, 60, 20132 Milano, MI , Italy"},{"name":"Vita-Salute San Raffaele University , Via Olgettina, 60, 20132 Milano, MI , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Ferrari","sequence":"additional","affiliation":[{"name":"San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute , Via Olgettina, 60, 20132 Milano, MI , Italy"},{"name":"Vita-Salute San Raffaele University , Via Olgettina, 60, 20132 Milano, MI , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Naldini","sequence":"additional","affiliation":[{"name":"San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute , Via Olgettina, 60, 20132 Milano, MI , Italy"},{"name":"Vita-Salute San Raffaele University , Via Olgettina, 60, 20132 Milano, MI , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"2023091507224421800_ref1","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.devcel.2021.05.018","article-title":"Niches that regulate stem cells and hematopoiesis in adult bone marrow","volume":"56","author":"Comazzetto","year":"2021","journal-title":"Dev Cell"},{"key":"2023091507224421800_ref2"},{"key":"2023091507224421800_ref3","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3324\/haematol.2019.245688","article-title":"History of hematopoietic cell transplantation: challenges and progress","volume":"105","author":"Granot","year":"2020","journal-title":"Haematologica"},{"key":"2023091507224421800_ref4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-030-02278-5_9","volume-title":"The EBMT Handbook","author":"Spierings","year":"2019"},{"key":"2023091507224421800_ref5","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-02278-5_12","volume-title":"Donor Selection for Adults and Pediatrics","author":"Ayuk","year":"2019"},{"key":"2023091507224421800_ref6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/sci-2021-058","article-title":"Racial disparities in hematopoietic stem cell transplant: a systematic review of the literature","volume":"8","author":"Landry","year":"2021","journal-title":"Stem Cell Investig"},{"key":"2023091507224421800_ref7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.05.013","article-title":"Peripheral blood stem and progenitor cell collection in pediatric candidates for ex vivo gene therapy: a 10-year series","volume":"22","author":"Canarutto","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2023091507224421800_ref8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2402893","article-title":"Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation?","volume":"17","author":"Heimfeld","year":"2003","journal-title":"Leukemia"},{"key":"2023091507224421800_ref9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.bbmt.2017.05.003","article-title":"Sources of hematopoietic stem and progenitor cells and methods to optimize yields for clinical cell therapy","volume":"23","author":"Panch","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023091507224421800_ref10","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s12015-021-10272-1","article-title":"Hematopoietic stem cell mobilization: current collection approaches, stem cell heterogeneity, and a proposed new method for stem cell transplant conditioning","volume":"17","author":"Menendez-Gonzalez","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"2023091507224421800_ref11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/leu.2012.254","article-title":"Hematopoietic stem cell mobilization: updated conceptual renditions","volume":"27","author":"Bonig","year":"2013","journal-title":"Leukemia"},{"key":"2023091507224421800_ref12","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19900515)65:10<2185::AID-CNCR2820651005>3.0.CO;2-4","article-title":"The colony stimulating factors discovery, development, and clinical applications","author":"Metcalf","year":"1990","journal-title":"Cancer"},{"key":"2023091507224421800_ref13","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1126\/science.289.5482.1202","article-title":"Inflammation dampened by gelatinase a cleavage of monocyte chemoattractant protein-3","volume":"289","author":"McQuibban","year":"2000","journal-title":"Science"},{"key":"2023091507224421800_ref14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V98.5.1289","article-title":"Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor","author":"L\u00e9vesque","year":"2001","journal-title":"Blood"},{"key":"2023091507224421800_ref15","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1182\/blood-2004-01-0272","article-title":"G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow","volume":"106","author":"Semerad","year":"2005","journal-title":"Blood"},{"key":"2023091507224421800_ref16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-030-02278-5_15","volume-title":"The EBMT Handbook","author":"H\u00fcbel","year":"2019"},{"key":"2023091507224421800_ref17","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2007-12-130179","article-title":"Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4\/SDF-1 interaction","volume":"112","author":"Devine","year":"2008","journal-title":"Blood"},{"key":"2023091507224421800_ref18","doi-asserted-by":"crossref","first-page":"204020661982938","DOI":"10.1177\/2040206619829382","article-title":"Mozobil\u00ae (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration","volume":"27","author":"De Clercq","year":"2019","journal-title":"Antivir Chem Chemother"},{"key":"2023091507224421800_ref19","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.3324\/haematol.2016.154740","article-title":"Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone","volume":"102","author":"Lidonnici","year":"2017","journal-title":"Haematologica"},{"key":"2023091507224421800_ref20","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.bbmt.2018.06.023","article-title":"Differences in cellular composition of peripheral blood stem cell grafts from healthy stem cell donors mobilized with either granulocyte Colony-stimulating factor (G-CSF) alone or G-CSF and Plerixafor","volume":"24","author":"Teipel","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023091507224421800_ref21","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1038\/s41375-020-0982-y","article-title":"Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization","volume":"34","author":"Mombled","year":"2020","journal-title":"Leukemia"},{"key":"2023091507224421800_ref22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12967-014-0240-z","article-title":"Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-\u03b1\u03b2\/CD19-depleted haploidentical stem cell grafts","volume":"12","author":"Rutella","year":"2014","journal-title":"J Transl Med"},{"key":"2023091507224421800_ref23","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.4049\/jimmunol.1301148","article-title":"Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with Plerixafor compared with G-CSF","volume":"191","author":"Lundqvist","year":"2013","journal-title":"J Immunol"},{"key":"2023091507224421800_ref24","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2008-10-184721","article-title":"BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells","volume":"114","author":"Ramirez","year":"2009","journal-title":"Blood"},{"key":"2023091507224421800_ref25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2011.197","article-title":"Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4","volume":"26","author":"Rettig","year":"2012","journal-title":"Leukemia"},{"key":"2023091507224421800_ref26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2006-06-031401","article-title":"The chemokine GRO\u03b2 mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment","volume":"110","author":"Fukuda","year":"2007","journal-title":"Blood"},{"key":"2023091507224421800_ref27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/978-1-4614-2098-9_11","article-title":"Mobilization and homing of hematopoietic stem cells","volume":"741","author":"Su\u00e1rez-\u00c1lvarez","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"2023091507224421800_ref28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/bloodadvances.2020003702","article-title":"In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal \u03b3-globin in \u03b2-YAC mice","volume":"5","author":"Li","year":"2021","journal-title":"Blood Adv"},{"key":"2023091507224421800_ref29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-030-02278-5_13","volume-title":"The EBMT Handbook","author":"Nagler","year":"2019"},{"key":"2023091507224421800_ref30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-3-030-02278-5_35","volume-title":"The EBMT Handbook","author":"Mikulska","year":"2019"},{"key":"2023091507224421800_ref31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-030-02278-5_23","volume-title":"The EBMT Handbook","author":"Schrezenmeier","year":"2019"},{"key":"2023091507224421800_ref32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/sj.bmt.1701800","article-title":"Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose","volume":"23","author":"Stewart","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"2023091507224421800_ref33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/978-3-030-02278-5_65","volume-title":"The EBMT Handbook","author":"Ciceri","year":"2019"},{"key":"2023091507224421800_ref34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"2023091507224421800_ref35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat Commun"},{"key":"2023091507224421800_ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201809958","article-title":"Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives","volume":"11","author":"Naldini","year":"2019","journal-title":"EMBO Mol Med"},{"key":"2023091507224421800_ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgeed.2021.618378","article-title":"Gene editing of hematopoietic stem cells: hopes and hurdles toward clinical translation","volume":"3","author":"Ferrari","year":"2021","journal-title":"Front Genome Ed"},{"key":"2023091507224421800_ref38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"key":"2023091507224421800_ref39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.stem.2023.04.014","article-title":"Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy","volume":"30","author":"Ferrari","year":"2023","journal-title":"Cell Stem Cell"},{"key":"2023091507224421800_ref40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat Rev Genet"},{"key":"2023091507224421800_ref41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.exphem.2005.12.014","article-title":"Decreased homing of retrovirally transduced human bone marrow CD34+ cells in the NOD\/SCID mouse model","volume":"34","author":"Hall","year":"2006","journal-title":"Exp Hematol"},{"key":"2023091507224421800_ref42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","article-title":"Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response","volume":"24","author":"Schiroli","year":"2019","journal-title":"Cell Stem Cell"},{"key":"2023091507224421800_ref43","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood.V85.9.2598.bloodjournal8592598","article-title":"Marrow- and spleen-seeding efficiencies of all murine hematopoietic stem cell subsets are decreased by preincubation with hematopoietic growth factors","volume":"85","author":"Loo","year":"1995","journal-title":"Blood"},{"key":"2023091507224421800_ref44","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V94.9.3055","article-title":"Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic\/severe combined immune deficiency mice: implications for stem cell frequency assessment","volume":"94","author":"Hennik","year":"1999","journal-title":"Blood"},{"key":"2023091507224421800_ref45","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41591-019-0550-z","article-title":"Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia","volume":"25","author":"R\u00edo","year":"2019","journal-title":"Nat Med"},{"key":"2023091507224421800_ref46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00007890-196803000-00018","article-title":"Fate of chromosome-marked mouse bone marrow cells tranfused into normal syngeneic recipients","volume":"6","author":"Micklem","year":"1968","journal-title":"Transplantation"},{"key":"2023091507224421800_ref47","first-page":"114","article-title":"Stem cell transplantation in the normal nonmyeloblasted host: relationship between cell dose, schedule, and engraftment","volume":"25","author":"Rao","year":"1997","journal-title":"Exp Hematol"},{"key":"2023091507224421800_ref48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-019-1244-x","article-title":"Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation","volume":"571","author":"Wilkinson","year":"2019","journal-title":"Nature"},{"key":"2023091507224421800_ref49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.stem.2015.10.004","article-title":"Phase I\/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft","volume":"18","author":"Wagner","year":"2016","journal-title":"Cell Stem Cell"},{"key":"2023091507224421800_ref50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-023-05739-9","article-title":"Chemically defined cytokine-free expansion of human haematopoietic stem cells","volume":"615","author":"Sakurai","year":"2023","journal-title":"Nature"},{"key":"2023091507224421800_ref51","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V91.10.3681.3681_3681_3687","article-title":"Lymphohematopoietic engraftment in minimally myeloablated hosts","volume":"91","author":"Stewart","year":"1998","journal-title":"Blood"},{"key":"2023091507224421800_ref52","first-page":"114","article-title":"Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment","volume":"25","author":"Rao","year":"1997","journal-title":"Exp Hematol"},{"key":"2023091507224421800_ref53","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41409-022-01728-0","article-title":"The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation","volume":"57","author":"Peci","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2023091507224421800_ref54","article-title":"\u201cTo condition\u201d or not \u201cto condition\u201d, this is the question","author":"Migliaccio","year":"2018","journal-title":"Exp Hematol"},{"key":"2023091507224421800_ref55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.stem.2014.06.001","article-title":"Kit regulates HSC engraftment across the human-mouse species barrier","volume":"15","author":"Cosgun","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2023091507224421800_ref56","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nmeth.1309","article-title":"Hematopoietic stem cell transplantation without irradiation","volume":"6","author":"Waskow","year":"2009","journal-title":"Nat Methods"},{"key":"2023091507224421800_ref57","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2003-07-2607","article-title":"Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD\/SCID repopulation","volume":"103","author":"Kahn","year":"2004","journal-title":"Blood"},{"key":"2023091507224421800_ref58","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1182\/blood-2005-07-2638","article-title":"Natural gene therapy in monozygotic twins with Fanconi anemia","volume":"107","author":"Mankad","year":"2006","journal-title":"Blood"},{"key":"2023091507224421800_ref59","doi-asserted-by":"crossref","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023091507224421800_ref60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-022-01284-6","article-title":"Worked to the bone: antibody-based conditioning as the future of transplant biology","volume":"15","author":"Griffin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2023091507224421800_ref61","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2023091507224421800_ref62","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"2023091507224421800_ref63","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"key":"2023091507224421800_ref64","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat Commun"},{"key":"2023091507224421800_ref65","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.cell.2022.04.039","article-title":"Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells","volume":"185","author":"Omer-Javed","year":"2022","journal-title":"Cell"},{"key":"2023091507224421800_ref66","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1182\/blood-2005-09-3593","article-title":"Mobilization as a preparative regimen for hematopoietic stem cell transplantation","volume":"107","author":"Chen","year":"2006","journal-title":"Blood"},{"key":"2023091507224421800_ref67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.omtm.2019.11.013","article-title":"Non-toxic HSC transplantation-based macrophage\/microglia-mediated GDNF delivery for Parkinson\u2019s disease","volume":"17","author":"Chen","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2023091507224421800_ref68","doi-asserted-by":"crossref","first-page":"e13110","DOI":"10.1111\/acel.13110","article-title":"Mobilization-based transplantation of young-donor hematopoietic stem cells extends lifespan in mice","volume":"19","author":"Guderyon","year":"2020","journal-title":"Aging Cell"},{"key":"2023091507224421800_ref69","doi-asserted-by":"crossref","first-page":"e13545","DOI":"10.15252\/emmm.202013545","article-title":"Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome","volume":"13","author":"Vavassori","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2023091507224421800_ref70","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.bbmt.2017.02.014","article-title":"Retrospective analysis of 37,287 observation years after peripheral blood stem cell donation","volume":"23","author":"Schmidt","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023091507224421800_ref71","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s41409-022-01656-z","article-title":"Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors \u2013 first 10 years of prospective donor follow-up of Swiss donors","volume":"57","author":"R\u00fcesch","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2023091507224421800_ref72","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/bloodadvances.2022007975","article-title":"In vivo HSC transduction in rhesus macaques with an HDAd5\/3 + vector targeting desmoglein 2 and transiently overexpressing cxcr4","volume":"6","author":"Wang","year":"2022","journal-title":"Blood Adv"},{"key":"2023091507224421800_ref73","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3324\/haematol.2016.150250","article-title":"Late effects of blood and marrow transplantation","volume":"102","author":"Inamoto","year":"2017","journal-title":"Haematologica"},{"key":"2023091507224421800_ref74","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2352-3026(23)00011-X","article-title":"Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial","volume":"10","author":"Grupp","year":"2023","journal-title":"Lancet Haematol"},{"key":"2023091507224421800_ref75","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/1744666X.2015.1041926","article-title":"Cytoreductive conditioning for severe combined immunodeficiency \u2013 help or hindrance?","volume":"11","author":"Laberko","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"2023091507224421800_ref76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bjh.14615","article-title":"How I manage patients with Fanconi anaemia","volume":"178","author":"Dufour","year":"2017","journal-title":"Br J Haematol"},{"key":"2023091507224421800_ref77","doi-asserted-by":"crossref","first-page":"eabl4106","DOI":"10.1126\/scitranslmed.abl4106","article-title":"Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models","volume":"14","author":"Birocchi","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023091507224421800_ref78","doi-asserted-by":"crossref","first-page":"e13598","DOI":"10.15252\/emmm.202013598","article-title":"Myeloid cell-based delivery of IFN-\u03b3 reprograms the leukemia microenvironment and induces anti-tumoral immune responses","volume":"13","author":"Mucci","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2023091507224421800_ref79","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bmt.2015.58","article-title":"Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation","volume":"50","author":"Konopleva","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"2023091507224421800_ref80","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/petr.12309","article-title":"A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency","volume":"18","author":"Dvorak","year":"2014","journal-title":"Pediatr Transplant"},{"key":"2023091507224421800_ref81","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1172\/JCI122836","article-title":"In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia","volume":"129","author":"Wang","year":"2019","journal-title":"J Clin Invest"},{"key":"2023091507224421800_ref82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-143113","article-title":"In vivo HSC gene therapy with base editors allows for efficient reactivation of Fetal globin in Beta-Yac mice","volume":"136","author":"Li","year":"2020","journal-title":"Blood"},{"key":"2023091507224421800_ref83","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood-2016-04-711580","article-title":"In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors","volume":"128","author":"Richter","year":"2016","journal-title":"Blood"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bmb\/article-pdf\/147\/1\/108\/51521781\/ldad017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bmb\/article-pdf\/147\/1\/108\/51521781\/ldad017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:24:02Z","timestamp":1694777042000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bmb\/article\/147\/1\/108\/7225323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,17]]},"published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1093\/bmb\/ldad017","relation":{},"ISSN":["0007-1420","1471-8391"],"issn-type":[{"value":"0007-1420","type":"print"},{"value":"1471-8391","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,7,17]]}}}